Conclusion:
We think that Methylene Blue as an inexpensive ubiquitously available
medication, has a considerable potential to be considered in treatment
of SARS COV2.
We did not have a rapid access to set-up of a clinical study and it was
prudent to share the idea with scientific community as soon as possible
in this special situation.
Paradoxical and unexpected effects have been observed in Methylene Blue
administration in other diseases if not meticulously done. Adverse
reaction may happen in patients with a history of serotonergic
medications as anti- depressants which may specially be prevalent these
days(27). So any clinical step must be taken cautiously. In the other
hand we must know that we are in a scrambling global health emergency
and too much obsessive methodology may leave us with many dead patients
to treat at the end of the day.
1. van de Veerdonk F, Netea MG, van Deuren M, van der Meer JW, de Mast
Q, Bruggemann RJ, et al. Kinins and Cytokines in COVID-19: A
Comprehensive Pathophysiological Approach. 2020.
2. Tolouian R, Vahed SZ, Ghiyasvand S, Tolouian A, Ardalan M. COVID-19
interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin
system; looking at a potential treatment. Journal of Renal Injury
Prevention. 2020;9(2).
3. Seyed-Mohammad Ghahestani M, Javad Mahmoudi P, Sakineh Hajebrahimi M,
4 , Amir-Babak Sioofy-Khojine D, PhD5,3,6*, Hanieh Salehi-Pourmehr P,
Fatemeh Sadeghi-Ghyassi P, et al. Bradykinin as a Probable Aspect in
SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?
. Iranian journal of allergy asthma and immunology( In- Press
publication). 2020.
4. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible
therapeutic option for the COVID-19. Travel medicine and infectious
disease. 2020.
5. Ko W-C, Rolain J-M, Lee N-Y, Chen P-L, Huang C-T, Lee P-I, et al.
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
International Journal of Antimicrobial Agents. 2020.
6. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental
treatment with favipiravir for COVID-19: an open-label control study.
Engineering. 2020.
7. Lim J, Jeon S, Shin H-Y, Kim MJ, Seong YM, Lee WJ, et al. Case of the
index patient who caused tertiary transmission of COVID-19 infection in
Korea: the application of lopinavir/ritonavir for the treatment of
COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of
Korean medical science. 2020;35(6).
8. Alhenc-Gelas F, Drueke TB. Blockade of SARS-CoV-2 infection by
recombinant soluble ACE2. Kidney International. 2020.
9. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al.
Angiotensin-converting enzyme 2 is a functional receptor for the SARS
coronavirus. Nature. 2003;426(6965):450-4.
10. Santos R, Ferreira AJ, Verano-Braga T, Bader M.
Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players
of the renin-angiotensin system. J endocrinol. 2013;216(2):R1-R17.
11. Liu Q, Zhou Y-h, Yang Z-q. The cytokine storm of severe influenza
and development of immunomodulatory therapy. Cellular & molecular
immunology. 2016;13(1):3-10.
12. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG.
Into the eye of the cytokine storm. Microbiol Mol Biol Rev.
2012;76(1):16-32.
13. Seyed-Mohammad Ghahestani M, Javad Mahmoudi P, Sakineh Hajebrahimi
M, 4 , Amir Babak Sioofy Khojine D, PhD5,3,6*, Hanieh Salehi-Pourmehr P,
Fatemeh Sadeghi-Ghyassi P, et al. Bradykinin as a Probable Aspect in
SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?. Iranian
journal of allergy asthma and immunology( In- Press publication). 2020.
14. Read R. Flawed methods in “COVID-19: Attacks the 1-Beta Chain of
Hemoglobin and Captures the Porphyrin to Inhibit Human Heme
Metabolism”. 2020.
15. Siehr S, Stuth E, Tweddell J, Hoffman G, Troshynski T, Jones D, et
al. Hypersensitivity reactions to aprotinin re-exposure in paediatric
surgery. European journal of cardio-thoracic surgery. 2010;37(2):307-11.
16. Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G. Interactions
among ACE, kinins and NO. Cardiovascular research. 1999;43(3):549-61.
17. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, et
al. Enzymatic function of hemoglobin as a nitrite reductase that
produces NO under allosteric control. The Journal of clinical
investigation. 2005;115(8):2099-107.
18. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions
of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics.
Arteriosclerosis, thrombosis, and vascular biology. 2006;26(4):697-705.
19. Rhaleb N-E, Dion S, Barabé J, Rouissi N, Jukic D, Drapeau G, et al.
Receptors for kinins in isolated arterial vessels of dogs. European
journal of pharmacology. 1989;162(3):419-27.
20. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis
by methylene blue. Biochemical pharmacology. 1993;45(2):367-74.
21. Yu B, Jin C, Zhang J, Wu H, Zhou X, Yao H, et al. Methylene blue
photochemical treatment as a reliable SARS-CoV-2 plasma virus
inactivation method for blood safety and convalescent plasma therapy for
the COVID-19 outbreak. 2020.
22. Henry M, Summa M, Patrick L, Schwartz L. A cohort of cancer patients
with no reported cases of SARS-CoV-2 infection: the possible preventive
role of Methylene Blue. Substantia. 2020:888-.
23. Galili Y, Kluger Y, Mianski Z, Iaina A, Wollman Y, Marmur S, et al.
Methylene blue–a promising treatment modality in sepsis induced by
bowel perforation. European surgical research. 1997;29(5):390-5.
24. Kwok ES, Howes D. Use of methylene blue in sepsis: a systematic
review. Journal of intensive care medicine. 2006;21(6):359-63.
25. Umbrello M, Gardinali M, Ottolina D, Zanforlin G, Iapichino G.
Systemic capillary leak syndrome: is methylene blue the silver bullet?
Case reports in critical care. 2014;2014.
26. Floyd RA, Schinazi RF. Antiviral therapy using thiazine dyes. Google
Patents; 2002.
27. Hencken L, To L, Ly N, Morgan JA. Serotonin syndrome following
methylene blue administration for vasoplegic syndrome. Journal of
cardiac surgery. 2016;31(4):208-10.